

Sheet 1 of 1

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P48B1USW	SERIAL NO. 10/520,143
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Alvaro et al.	
		FILING DATE January 17, 2008	GROUP

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
/CC/	1	US-8 097 029-A	07-09-1983	Janssen et al.		

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No
/CC/	2	BE-601228	03-31-1991	BE		x
	3	JP-04 089478-A	03-23-1992	JP	x Ab	
	4	WO-0037470	06-29-2000	WO		
	5	WO-93 01169-A	01-21-1993	WO		
/CC/	6	WO-94 04494-A	03-03-1994	WO		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

/CC/	7	European International Search Report containing information on BE601228.; February 22, 2000;
	8	GW MULLER ET AL.; Structural Modifications of the Thalidomide Prodrug Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity; J. Med. Chem.; 16 Aug 1996; 39/17; 3239-3240; ACS: Washington, DC
/CC/	9	M.D. BRION; J. Med. Chem.; 1993; 36/24; 3771-3783; ACS: Washington, DC

Examiner Signature /Celia Chang/	Date Considered 10/15/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	